> top > docs > PubMed:32603531 > spans > 89-333 > annotations

PubMed:32603531 / 89-333 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 166-171 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 166-171 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T2 225-233 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 234-243 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T2 4-7 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T3 156-161 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T4 166-171 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 62-72 Chemical denotes febuxostat http://purl.obolibrary.org/obo/CHEBI_31596
T2 98-116 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T4 0-244 Sentence denotes The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection.